
|Articles|April 1, 2005
Miravant starts phase III restaporfin trials
Santa Barbara, CA—Miravant Medical Technologies will conduct phase III clinical trials for rostaporfin (PHOTREX) at 50 investigational sites in central and eastern Europe and the United Kingdom to evaluate a range of patients with wet age-related macular degeneration.
Advertisement
Santa Barbara, CA-Miravant Medical Technologies will conduct phase III clinical trials for rostaporfin (PHOTREX) at 50 investigational sites in central and eastern Europe and the United Kingdom to evaluate a range of patients with wet age-related macular degeneration.
The FDA will review the randomized, placebo-controlled trial under a Special Protocol Assessment.
The company plans to conduct a primary efficacy endpoint analysis at 12 months of about 600 patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
3
Opuviz aflibercept biosimilar launches in Europe for retinal diseases
4
Study links alcohol consumption to earlier advanced presbyopia in men
5





















